Tumor microenvironment–responsive nanoformulations for breast cancer
Source abstract
Abstract
Nanomedicine, the most promising approach for regulated and targeted drug delivery, is frequently applied in cancer treatment. Essentially, accumulating evidence indicates that nanomedicine has positive results in the treatment of breast cancer (BC), with many BC patients benefiting from nanomedicine-related treatments. Currently, nanodrug delivery systems based on stimulus responses are gaining popularity because of their additional ability to manage drug release depending on the interior environment of the cancer. This review includes a synopsis of several types of internal (pH, redox, enzyme, reactive oxygen species, and hypoxia) stimuli-responsive nanoparticle drug delivery systems as well as perspectives for forthcoming times. Stimulus-responsive nanoparticles can remain stable under physiological conditions while being rapidly activated to release drugs in response to specific stimuli, prolonging blood circulation and increasing cancer cellular uptake, resulting in excellent therapeutic performance and improved biosafety. In this paper, we discuss tumor microenvironment responsive Nanoformulation for breast cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA: Cancer J Clin. 2017;67:439–48. https://doi.org/10.3322/caac.21412.10.3322/caac.21412 ↗
2. Hosonaga M, Saya H, Arima Y. Molecular and cellular mechanisms underlying brain metastasis of breast cancer. Cancer Metastasis Rev. 2020;39:711–20. https://doi.org/10.1007/s10555-020-09881-y.10.1007/s10555-020-09881-y ↗
3. Cui F, Liu J, Pang S, Li B. Recent advance in tumor microenvironment-based stimuli-responsive nanoscale drug delivery and imaging platform. Front Pharmacol. 2022;22(13): 929854. https://doi.org/10.3389/fphar.2022.929854. (PMID: 35935835 PMCID: PMC9354407).10.3389/fphar.2022.929854 ↗
4. Chamundeeswari M, Jeslin J, Verma ML. Nanocarriers for drug delivery applications. Environ Chem Lett. 2018;17(2):849–65. https://doi.org/10.1007/s10311-018-00841-1.10.1007/s10311-018-00841-1 ↗
5. Chau Y, Zhong J. Enzyme-sensitive biomaterials for drug delivery. Compr Biotechnol. 2011;5:605–24. https://doi.org/10.1016/b978-0-08-088504-9.00158-6.10.1016/b978-0-08-088504-9.00158-6 ↗
6. Heppner GH, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 1983;2:5–23. https://doi.org/10.1007/BF00046903.10.1007/BF00046903 ↗
7. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea–a paradigm shift. Cancer Res. 2006;66:1883–90. https://doi.org/10.1158/0008-5472.CAN-05-3153. (discussion 1895–1886).10.1158/0008-5472.CAN-05-3153 ↗
8. Chen M, Liu D, Liu F, Wu Y, Peng X, Song F. Recent advances of redox-responsive nanoplatforms for tumor theranostics. J Control Release. 2021;332:269–84. https://doi.org/10.1016/j.jconrel.2021.02.030.10.1016/j.jconrel.2021.02.030 ↗
9. Han SS, Li ZY, Zhu JY, Han K, Zeng ZY, Hong W, et al. Dual-pH sensitive charge-reversal polypeptide micelles for tumor-triggered targeting uptake and nuclear drug delivery. Small. 2015;11:2543–54. https://doi.org/10.1002/smll.201402865.10.1002/smll.201402865 ↗
10. Jhaveri AM, Torchilin VP. Multifunctional polymeric micelles for delivery of drugs and siRNA. Front Pharmacol. 2014;5:77. https://doi.org/10.3389/fphar.2014.00077.10.3389/fphar.2014.00077 ↗
11. Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18:157. https://doi.org/10.1186/s12943-019-1089-9.10.1186/s12943-019-1089-9 ↗
12. Dai Y, Xu C, Sun X, Chen X. Nanoparticle design strategies for enhanced anticancer therapy by exploiting the tumor microenvironment. Chem Soc Rev. 2017;46:3830–52. https://doi.org/10.1039/C6CS00592F.10.1039/C6CS00592F ↗
13. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–49. https://doi.org/10.3322/caac.21660. (PubMed).10.3322/caac.21660 ↗
14. Qin S-Y, Cheng Y-J, Lei Q, Zhang A-Q, Zhang X-Z. Combinational strategy for high-performance cancer chemotherapy. Biomaterials. 2018;171:178–97. https://doi.org/10.1016/j.biomaterials.2018.04.027. (PubMed).10.1016/j.biomaterials.2018.04.027 ↗
15. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. Pt 23J. Cell Sci. 2012;125:5591–6. https://doi.org/10.1242/jcs.116392. (PubMed).10.1242/jcs.116392 ↗
16. Yang S, Gao H. Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmocol Res. 2017;126:97–108. https://doi.org/10.1016/j.phrs.2017.05.004.10.1016/j.phrs.2017.05.004 ↗
17. Moreira AF, Dias DR, Correia IJ. Stimuli-responsive mesoporous silica nanoparticles for cancer therapy: a review. Micropor Mesopor Mat. 2016;236:141–57.10.1016/j.micromeso.2016.08.038 ↗
18. Bailey KM, Wojtkowiak JW, Cornnell HH, Ribeiro MC, Balagurunathan Y, Hashim AI, Gillies RJ. Mechanisms of buffer therapy resistance. Neoplasia. 2014;16(354–364):e351-353.
19. Bogurcu N, Seidel S, Garvalov BK, Acker T. Analysis of hypoxia and the hypoxic response in tumor Xenografts. Methods Mol Biol. 2018;1742:283–300.10.1007/978-1-4939-7665-2_25 ↗
20. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.10.1126/science.1104819 ↗
21. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730–56.10.1016/S1470-2045(08)70179-7 ↗
22. Jain V, Kumar H, Anod HV, Chand P, Gupta NV, Dey S, et al. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer. J Control Release. 2020;10(326):628–47.10.1016/j.jconrel.2020.07.003 ↗
23. Delgado JL, Herranz MA, León NM. Nanoestructuras de carbono: un nuevo desafío científico. An Quim. 2020;103(4):5–13.
24. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997–2008.10.1056/NEJM200106283442607 ↗
25. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 2010;10:337.10.1186/1471-2407-10-337 ↗
26. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O’Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol. 2007;7(8):657–67. https://doi.org/10.1016/S1470-2045(06)70793-8.10.1016/S1470-2045(06)70793-8 ↗
27. Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, et al. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Can Res. 2013;73(8):2412–7. https://doi.org/10.1158/0008-5472.CAN-12-4561.10.1158/0008-5472.CAN-12-4561 ↗
28. Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v8–30. https://doi.org/10.1093/annonc/mdv298.10.1093/annonc/mdv298 ↗
29. Morris SA, Farrell D, Grodzinski P. Nanotechnologies in cancer treatment and diagnosis. J Natl Compr Canc Netw. 2014;12(12):1727–33. https://doi.org/10.4172/2155-9619.1000195.10.4172/2155-9619.1000195 ↗
30. Koushik O, Rao Y, Kumar P, Karthikeyan R. Nano drug delivery systems to overcome cancer drug resistance-a review. J Nanomed Nanotechnol. 2016;7(378):2. https://doi.org/10.4172/2157-7439.1000378.10.4172/2157-7439.1000378 ↗
31. Johnson R, Sabnis N, McConathy WJ, Lacko AG. The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics. 2013;5(2):353–70. https://doi.org/10.3390/pharmaceutics5020353.10.3390/pharmaceutics5020353 ↗
32. Shi Y, Lammers T. Combining nanomedicine and immunotherapy. Acc Chem Res. 2019;52:1543–54. https://doi.org/10.1021/acs.accounts.9b00148.10.1021/acs.accounts.9b00148 ↗
33. World Health Organization (2018) Cancer Fact Sheet. WHO Media Centre
34. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates ofincidence and mortality worldwide for 36 cancers in 185Countries. Ca-Cancer J Clin. 2021;71:209. https://doi.org/10.3322/caac.21660.10.3322/caac.21660 ↗
35. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Ca-Cancer. J Clin. 2018;68:394. https://doi.org/10.3322/caac.21492.10.3322/caac.21492 ↗
36. Kamb A. What’s wrong with our cancer models? Nat Rev Drug Discov. 2005;4:161–5. https://doi.org/10.1038/nrd1635.10.1038/nrd1635 ↗
37. Nam J, Son S, Park K, et al. Cancer nanomedicine for combination cancer immunotherapy. Nat Rev Mater. 2019;4:398–414. https://doi.org/10.1038/s41578-019-0108-1.10.1038/s41578-019-0108-1 ↗
38. Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T-cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–68. https://doi.org/10.1038/s41577-020-0306-5. (Epub 2020 May 20 PMID: 32433532 PMCID: PMC7238960).10.1038/s41577-020-0306-5 ↗
39. Zhang W, Wang F, Hu C, et al. The progress and perspective of nanoparticle-enabled tumor metastasis treatment. Acta Pharmaceutica Sinica B. 2020;10(11):2037–53. https://doi.org/10.1016/j.apsb.2020.07.013. (PMID: 33304778 PMCID: PMC7714986).10.1016/j.apsb.2020.07.013 ↗
40. Peng S, Wang H, Xin Y, Zhao W, Zhan M, Li J, Cai R, Lu L. Second near-infrared photoactivatable hydrogen selenide nanogenerators for metastasis-inhibited cancer therapy. Nano Today. 2021;40: 101240. https://doi.org/10.1016/j.nantod.2021.101240.10.1016/j.nantod.2021.101240 ↗
41. Yu W, Liu R, Zhou Y, Gao H. Size-tunable strategies for a tumor targeted drug delivery system ACS. Cent Sci. 2020;6:100. https://doi.org/10.1021/acscentsci.9b01139.10.1021/acscentsci.9b01139 ↗
42. Wang D, Wang T, Liu J, Yu H, Jiao S, Feng B, Zhou F, Fu Y, Yin Q, Zhang P, Zhang Z, Zhou Z, Li Y. Acid-activatable versatile micelleplexes for PD-L1 blockade-enhanced cancer photodynamic immunotherapy. Nano Lett. 2016;16(9):5503–13. https://doi.org/10.1021/acs.nanolett.6b01994. (Epub 2016 Aug 17 PMID: 27525587).10.1021/acs.nanolett.6b01994 ↗
43. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer. 2013;108(1):1–8. https://doi.org/10.1038/bjc.2012.569.10.1038/bjc.2012.569 ↗
44. Khawar IA, Kim JH, Kuh HJ. Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release. 2015;10(201):78–89. https://doi.org/10.1016/j.jconrel.2014.12.018. (Epub 2014 Dec 17 PMID: 25526702).10.1016/j.jconrel.2014.12.018 ↗
45. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine. 2010;5(4):597–615. https://doi.org/10.2217/nnm.10.35. (PMID: 20528455 PMCID: PMC2925023).10.2217/nnm.10.35 ↗
46. Minko T, Rodriguez-Rodriguez L, Pozharov V. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev. 2013;65(13–14):1880–95. https://doi.org/10.1016/j.addr.2013.09.017. (Epub 2013 Oct 10 PMID: 24120655).10.1016/j.addr.2013.09.017 ↗
47. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14(3):275–91. https://doi.org/10.1016/j.stem.2014.02.006. (PMID: 24607403).10.1016/j.stem.2014.02.006 ↗
48. Kise K, Kinugasa-Katayama Y, Takakura N. Tumor microenvironment for cancer stem cells. Adv Drug Deliv Rev. 2016;99(Pt B):197–205. https://doi.org/10.1016/j.addr.2015.08.005. (Epub 2015 Sep 8 PMID: 26362921).10.1016/j.addr.2015.08.005 ↗
49. Alamoudi K, Martins P, Croissant JG, Patil S, Omar H, Khashab NM. Thermoresponsive pegylated bubble liposome nanovectors for efficient siRNA delivery via endosomal escape. Nanomedicine. 2017;12(12):1421–33. https://doi.org/10.2217/nnm-2017-0021. (Epub 2017 May 19 PMID: 28524721).10.2217/nnm-2017-0021 ↗
50. Gao M, Xu Y, Qiu L. Sensitization of multidrug-resistant malignant cells by liposomes coencapsulating doxorubicin and chloroquine through autophagic inhibition. J Liposome Res. 2017;27(2):151–60. https://doi.org/10.1080/08982104.2016.1185731. (Epub 2016 Jun 2 PMID: 27250110).10.1080/08982104.2016.1185731 ↗
51. Muddineti OS, Kumari P, Ray E, Ghosh B, Biswas S. Curcumin-loaded chitosan-cholesterol micelles: evaluation in monolayers and 3D cancer spheroid model. Nanomedicine. 2017;12(12):1435–53. https://doi.org/10.2217/nnm-2017-0036. (Epub 2017 Jun 2 PMID: 28573926).10.2217/nnm-2017-0036 ↗
52. Huang SY, Liu JY, Zhu H, Hussain A, Liu Q, Li J, et al. PEGylated doxorubicin micelles loaded with curcumin exerting synergic effects on multidrug resistant tumor cells. J Nanosci Nanotechnol. 2017;17:2873–80. https://doi.org/10.1166/jnn.2017.13047.10.1166/jnn.2017.13047 ↗
53. Wang Y, Zhang Z, Xu S, Wang F, Shen Y, Huang S, Guo S. pH, redox and photothermal tri-responsive DNA/polyethylenimine conjugated gold nanorods as nanocarriers for specific intracellular corelease of doxorubicin and chemosensitizer pyronaridine to combat multidrug resistant cancer. Nanomedicine. 2017;13(5):1785–95. https://doi.org/10.1016/j.nano.2017.01.014. (Epub 2017 Feb 6 PMID: 28185939).10.1016/j.nano.2017.01.014 ↗
54. Zhang Q, Kuang G, Li W, Wang J, Ren H, Zhao Y. Stimuli-responsive gene delivery nanocarriers for cancer therapy. Nanomicro Lett. 2023;15(1):44. https://doi.org/10.1007/s40820-023-01018-4. (PMID: 36752939 PMCID: PMC9908819).10.1007/s40820-023-01018-4 ↗
55. Glover DJ, Leyton DL, Moseley GW, Jans DA. The efficiency of nuclear plasmid DNA delivery is a critical determinant of transgene expression at the single cell level. J Gene Med. 2010;12(1):77–85. https://doi.org/10.1002/jgm.1406. (PMID: 19890943).10.1002/jgm.1406 ↗
56. Naeem M, Majeed S, Hoque MZ, Ahmad I. Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing. Cells. 2020;9(7):1608. https://doi.org/10.3390/cells9071608.PMID:32630835;PMCID:PMC7407193.10.3390/cells9071608.PMID:32630835;PMCID:PMC7407193 ↗
57. Fang T, Cao X, Ibnat M, Chen G. Stimuli-responsive nanoformulations for CRISPR-Cas9 genome editing. J Nanobiotechnol. 2022;20(1):354. https://doi.org/10.1186/s12951-022-01570-y. (PMID: 35918694 PMCID: PMC9344766).10.1186/s12951-022-01570-y ↗
58. van Beilen JB, Li Z. Enzyme technology: an overview. Curr Opin Biotechnol. 2002;13(4):338–44. https://doi.org/10.1016/s0958-1669(02)00334-8. (PMID: 12323356).10.1016/s0958-1669(02)00334-8 ↗
59. Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J Hematol Oncol. 2018;11:125. https://doi.org/10.1186/s13045-018-0669-2.10.1186/s13045-018-0669-2 ↗
60. Cheng X, Zhang H, Hamad A, Huang H, Tsung A. Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol. 2022;86:408–19. https://doi.org/10.1016/j.semcancer.2022.01.006.10.1016/j.semcancer.2022.01.006 ↗
61. Gay LJ, Felding-Habermann B. Contribution of platelets to tumor metastasis. Nat Rev Cancer. 2011;11:123–34. https://doi.org/10.1038/nrc3004.10.1038/nrc3004 ↗
62. Suzuki-Inoue K. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin. Blood. 2019;134:1912–8. https://doi.org/10.1182/blood.2019001388.10.1182/blood.2019001388 ↗
63. Bruno A, Dovizio M, Tacconelli S, Contursi A, Ballerini P, Patrignani P. Antithrombotic agents and cancer. Cancers. 2018;10:253. https://doi.org/10.3390/cancers10080253.10.3390/cancers10080253 ↗
64. Zhu YS, Tang K, Lv J. Peptide-drug conjugate-based novel molecular drug delivery system in cancer. Trends Pharmacol Sci. 2021;42:857–69. https://doi.org/10.1016/j.tips.2021.07.001.10.1016/j.tips.2021.07.001 ↗
65. Alexander ET, Gilmour SK. Immunomodulatory role of thrombin in cancer progression. Mol Carcinog. 2022;61:527–36.10.1002/mc.23398 ↗
66. García-López MT, Gutiérrez-Rodríguez M, Herranz R. Thrombin-activated receptors: promising targets for cancer therapy? Curr Med Chem. 2010;17:109–28. https://doi.org/10.2174/092986710790112639.10.2174/092986710790112639 ↗
67. Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30:2362–7. https://doi.org/10.1161/ATVBAHA.110.207514.10.1161/ATVBAHA.110.207514 ↗
68. Gnanenthiran SR, Pennings GJ, Reddel CJ, et al. Identification of a distinct platelet phenotype in elderly individuals: ADP hypersensitivity coexists with platelet PAR (Protease-Activated Receptor)-1 and PAR-4-mediated thrombin resistance. Arterioscler Thromb Vasc Biol. 2022;42:960–72. https://doi.org/10.1161/ATVBAHA.120.316772.10.1161/ATVBAHA.120.316772 ↗
69. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008;7(9):771–82. https://doi.org/10.1038/nrd2614. (PMID: 18758474).10.1038/nrd2614 ↗
70. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13(11):813–27. https://doi.org/10.1038/nrd4333. (Epub 2014 Oct 7 PMID: 25287120 PMCID: PMC4489143).10.1038/nrd4333 ↗
71. Murakami M, Cabral H, Matsumoto Y, Wu S, Kano MR, Yamori T, Nishiyama N, Kataoka K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. Sci Transl Med. 2011;3(64):64ra2. https://doi.org/10.1126/scitranslmed.3001385. (PMID: 21209412).10.1126/scitranslmed.3001385 ↗
72. Du JZ, Du XJ, Mao CQ, Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J Am Chem Soc. 2011;133(44):17560–3. https://doi.org/10.1021/ja207150n. (Epub 2011 Oct 17 PMID: 21985458).10.1021/ja207150n ↗
73. Ling D, Park W, Park SJ, Lu Y, Kim KS, Hackett MJ, Kim BH, Yim H, Jeon YS, Na K, Hyeon T. Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J Am Chem Soc. 2014;136(15):5647–55. https://doi.org/10.1021/ja4108287. (Epub 2014 Apr 1 PMID: 24689550).10.1021/ja4108287 ↗
74. Albanese A, Lam AK, Sykes EA, Rocheleau JV, Chan WC. Tumor-on-a-chip provides an optical window into nanoparticle tissue transport. Nat Commun. 2013;4:2718. https://doi.org/10.1038/ncomms3718. (PMID: 24177351 PMCID: PMC3947376).10.1038/ncomms3718 ↗
75. Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, Zhang J, He S, Liang XJ. Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res. 2013;73(1):319–30. https://doi.org/10.1158/0008-5472.CAN-12-2071. (Epub 2012 Oct 16 PMID: 23074284).10.1158/0008-5472.CAN-12-2071 ↗
76. Kolate A, Baradia D, Patil S, Vhora I, Kore G, Misra A. PEG—a versatile conjugating ligand for drugs and drug delivery systems. J Control Release. 2014;28(192):67–81. https://doi.org/10.1016/j.jconrel.2014.06.046. (Epub 2014 Jul 2 PMID: 24997275).10.1016/j.jconrel.2014.06.046 ↗
77. Guo Y, Jiang K, Shen Z, Zheng G, Fan L, Zhao R, Shao J. A small molecule nanodrug by self-assembly of dual anticancer drugs and photosensitizer for synergistic near-infrared cancer theranostics. ACS Appl Mater Interfaces. 2017;9:43508–19. https://doi.org/10.1021/acsami.7b14755.10.1021/acsami.7b14755 ↗
78. Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget. 2017;8(1):1913–24. https://doi.org/10.18632/oncotarget.12284. (PMID: 27765921 PMCID: PMC5352107).10.18632/oncotarget.12284 ↗
79. Nofech-Mozes S, Trudeau M, Kahn HK, et al. Patterns of recurrence in the basal and nonbasal subtypes of triple-negative breast cancers. Breast Cancer Res Treat. 2009;118:131–7. https://doi.org/10.1007/s10549-008-0295-8.10.1007/s10549-008-0295-8 ↗
80. Cai K, He X, Song Z, Yin Q, Zhang Y, Uckun FM, Jiang C, Cheng J. Dimeric drug polymeric nanoparticles with exceptionally high drug loading and quantitative loading efficiency. Am Chem Soc. 2015;137:3458. https://doi.org/10.1021/ja513034e.10.1021/ja513034e ↗
81. Roger E, Lagarce F, Benoit JP. Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration. Eur J Pharm Biopharm. 2011;79:181–8. https://doi.org/10.1016/j.ejpb.2011.01.021.10.1016/j.ejpb.2011.01.021 ↗
82. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393–410. https://doi.org/10.1038/nrc3064. (PMID: 21606941).10.1038/nrc3064 ↗
83. Bailey KM, Wojtkowiak JW, Hashim AI, Gillies RJ. Targeting the metabolic microenvironment of tumors. Adv Pharmacol. 2012;65:63–107. https://doi.org/10.1016/B978-0-12-397927-8.00004-X. (PMID: 22959024 PMCID: PMC3796340).10.1016/B978-0-12-397927-8.00004-X ↗
84. Kling J. Hypoxia-activated prodrugs forge ahead in cancer. Nat Biotechnol. 2012;30(5):381. https://doi.org/10.1038/nbt0512-381. (PMID: 22565952).10.1038/nbt0512-381 ↗
85. Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, Hart CP. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res. 2012;18(3):758–70. https://doi.org/10.1158/1078-0432.CCR-11-1980. (Epub 2011 Dec 19).10.1158/1078-0432.CCR-11-1980 ↗
86. Lin Q, Bao C, Yang Y, Liang Q, Zhang D, Cheng S, Zhu L. Highly discriminating photorelease of anticancer drugs based on hypoxia activatable phototrigger conjugated chitosan nanoparticles. Adv Mater. 2013;25(14):1981–6. https://doi.org/10.1002/adma.201204455. (Epub 2013 Feb 7 PMID: 23401259).10.1002/adma.201204455 ↗
87. Thambi T, Deepagan VG, Yoon HY, Han HS, Kim SH, Son S, Jo DG, Ahn CH, Suh YD, Kim K, Kwon IC, Lee DS, Park JH. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery. Biomaterials. 2014;35(5):1735–43. https://doi.org/10.1016/j.biomaterials.2013.11.022. (Epub 2013 Nov 26 PMID: 24290696).10.1016/j.biomaterials.2013.11.022 ↗
88. Perche F, Biswas S, Wang T, Zhu L, Torchilin VP. Hypoxia-targeted siRNA delivery. Angew Chem Int Ed Engl. 2014;53(13):3362–6. https://doi.org/10.1002/anie.201308368. (Epub 2014 Feb 19. PMID: 24554550; PMCID: PMC4150469).10.1002/anie.201308368 ↗
89. Heppner GH, Miller BE. Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metastasis Rev. 1983;2(1):5–23. https://doi.org/10.1007/BF00046903. (PMID: 6616442).10.1007/BF00046903 ↗
90. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea–a paradigm shift. Cancer Res. 2006;66(4):1883–90. https://doi.org/10.1158/0008-5472.CAN-05-3153. (PMID: 16488983).10.1158/0008-5472.CAN-05-3153 ↗
91. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65(23):10946–51. https://doi.org/10.1158/0008-5472.CAN-05-2018. (PMID: 16322242).10.1158/0008-5472.CAN-05-2018 ↗
92. Marcucci F, Stassi G, De Maria R. Epithelial–mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov. 2016;15:311–25. https://doi.org/10.1038/nrd.2015.13.10.1038/nrd.2015.13 ↗
93. McAtee CO, Barycki JJ, Simpson MA. Emerging roles for hyaluronidase in cancer metastasis and therapy. Adv Cancer Res. 2014;123:1–34. https://doi.org/10.1016/B978-0-12-800092-2.00001-0.10.1016/B978-0-12-800092-2.00001-0 ↗
94. Oh ET, Park HJ. Implications of NQO1 in cancer therapy. BMB Rep. 2015;48:609–17. https://doi.org/10.5483/BMBRep.2015.48.11.190.10.5483/BMBRep.2015.48.11.190 ↗
95. Hua S. Orally administered liposomal formulations for colon targeted drug delivery. Front Pharmacol. 2014;5:138. https://doi.org/10.3389/fphar.2014.00138.10.3389/fphar.2014.00138 ↗
96. Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract—influence of physiological, pathophysiological and pharmaceutical factors. Front Pharmacol. 2020;11:524. https://doi.org/10.3389/fphar.2020.10.3389/fphar.2020 ↗
97. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 2011;102:1247–52. https://doi.org/10.1111/j.1349-7006.2011.01941.10.1111/j.1349-7006.2011.01941 ↗
98. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–51. https://doi.org/10.1038/nbt.3330.10.1038/nbt.3330 ↗
99. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67. https://doi.org/10.1016/0092-8674(90)90186-i.10.1016/0092-8674(90)90186-i ↗
100. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–60. https://doi.org/10.1038/nnano.2007.387. (PMID: 18654426).10.1038/nnano.2007.387 ↗